Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations

Summary

Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder characterised by quantitative and/or qualitative defects of the platelet glycoprotein (GP) IIb/IIIa complex, also called integrin αIIbβ3. αIIbβ3 is well known as a platelet fibrinogen receptor and mediates platelet aggregation, firm adhesion, and spreading. This study describes the molecular genetic analyses of 19 patients with GT who were diagnosed on the basis of clinical parameters and platelet analyses. The patients’ bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, gastrointestinal bleeding, and menorrhagia. Homozygous or compound heterozygous mutations in ITGA2B or ITGB3 were identified as causing GT by sequencing of genomic DNA. All exons including exon/intron boundaries of both genes were analysed. In a patient with an intronic mutation, splicing of mRNA was analysed using reverse transcriptase (RT)-PCR of platelet-derived RNA. In short, 16 of 19 patients revealed 27 different mutations (ITGA2B: n=17, ITGB3: n=10). Seventeen of these mutations have not been published to date. Mutations in ITGA2B or ITGB3 were identified as causing GT in 16 patients. We detected a total of 27 mutations in ITGA2B and ITGB3 including 17 novel missense, nonsense, frameshift and splice site mutations. In addition, three patients revealed no molecular genetic anomalies in ITGA2B or ITGB3 that could explain the suspected diagnosis of GT. We assume that these patients may harbour defects in a regulatory element affecting the transcription of these genes, or other proteins may exist that are important for activating the αIIbβ3 complex that may be affected.

Keywords

Glanzmann thrombasthenia - platelet function defect - glycoprotein αIIbβ3

• References

• 1 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-1395.
• 2 Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 01: 10.
• 3 Nurden AT, Fiore M, Nurden P. et al. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
• 4 Bray PF, Barsh G, Rosa JP. et al. Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIa. Proc Natl Acad Sci USA 1988; 85: 8683-8687.
• 5 Heidenreich R, Eisman R, Surrey S. et al. Organization of the gene for platelet glycoprotein IIb. Biochemistry 1990; 29: 1232-1244.
• 6 Wilhide CC, Jin Y, Guo Q. et al. The human integrin beta3 gene is 63 kb and contains a 5'-UTR sequence regulating expression. Blood 1997; 90: 3951-3961.
• 7 Bray PF, Rosa JP, Lingappa VR. et al. Biogenesis of the platelet receptor for fibrinogen:evidence for separate precursors for glycoproteins IIb and IIIa. Proc Natl Acad Sci USA 1986; 83: 1480-1484.
• 8 Rosenberg N, Yatuv R, Sobolev V. et al. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 2003; 101: 4808-4815.
• 9 O'Toole TE, Loftus JC, Plow EF. et al. Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood 1989; 74: 14-18.
• 10 Lahav J, Jurk K, Hess O. et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100: 2472-2478.
• 11 Santoso S, Kiefel V, Richter IG. et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta(3) integrin: the Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002; 99: 1205-1214.
• 12 Vannier C, Behnisch W, Bartsch I. et al. Novel homozygous mutation (c.175delG) in platelet glycoprotein ITGA2B gene as cause of Glanzmann's thrombasthenia type I. Klin Padiatr 2010; 222: 150-153.
• 13 D'Andrea G, Colaizzo D, Vecchione G. et al. Glanzmann's thrombasthenia:identification of 19 new mutations in 30 patients. Thromb Haemost 2002; 87: 1034-1042.
• 14 Kannan M, Ahmad F, Yadav BK. et al. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. J Thromb Haemost 2009; 07: 1878-1885.
• 15 Nelson EJ, Nair SC, Peretz H. et al. Diversity of Glanzmann thrombasthenia in southern India: 10 novel mutations identified among 15 unrelated patients. J Thromb Haemost 2006; 04: 1730-1737.
• 16 Grimaldi CM, Chen F, Wu C. et al. Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-1571.
• 17 French DL, Coller BS. Hematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol Dis 1997; 23: 39-51.
• 18 Ambo H, Kamata T, Handa M. et al. Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol 1998; 102: 829-840.
• 19 Tadokoro S, Tomiyama Y, Honda S. et al. A Gln747-->Pro substitution in the IIb subunit is responsible for a moderate IIbbeta3 deficiency in Glanzmann thrombasthenia. Blood 1998; 92: 2750-2758.
• 20 Vijapurkar M, Ghosh K, Shetty S. Novel mutations in GP IIb gene in Glanzmann's thrombasthenia from India. Platelets 2009; 20: 35-40.
• 21 Jallu V, Dusseaux M, Panzer S. et al. AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function. Hum Mutat 2010; 31: 237-246.
• 22 Sandrock K, Halimeh S, Wiegering V. et al. Homozygous point mutations in platelet glycoprotein ITGA2B gene as cause of Glanzmann thrombasthenia in 2 families. Klin Padiatr 2012; 224: 174-178.
• 23 Vinciguerra C, Bordet JC, Beaune G. et al. Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) and glycoprotein IIIa (beta3) genes. Platelets 2001; 12: 486-495.
• 24 Kato A, Yamamoto K, Miyazaki S. et al. Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex. Blood 1992; 79: 3212-3218.
• 25 Nair S, Li J, Mitchell WB. et al. Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3. Thromb Haemost 2002; 88: 503-509.
• 26 Jin Y, Dietz HC, Montgomery RA. et al. Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. J Clin Invest 1996; 98: 1745-1754.
• 27 Pillitteri D, Pilgrimm AK, Kirchmaier CM. Novel Mutations in the GPIIb and GPIIIa Genes in Glanzmann Thrombasthenia. Transfus Med Haemother 2010; 37: 268-277.
• 28 Ruan J, Peyruchaud O, Alberio L. et al. Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia. Br J Haematol 1998; 102: 918-925.
• 29 Arias-Salgado EG, Tao J, Gonzalez-Manchon C. et al. Nonsense mutation in exon-19 of GPIIb associated with thrombasthenic phenotype. Failure of GPIIb(delta597-1008) to form stable complexes with GPIIIa. Thromb Haemost 2002; 87: 684-691.
• 30 Rosenberg N, Hauschner H, Peretz H. et al. A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost 2005; 03: 2764-2772.
• 31 Ambo H, Kamata T, Handa M. et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun 1998; 251: 763-768.